Table 3

Summary of the diagnostic value of ActiTest for the diagnosis of necroinflammatory hepatic activity (AUROC) in patients with chronic hepatitis C, from the published studies.
First author, Year
 Patient number
 Methodology
 Marker
 Grade/Prevalence
 AUROC (SE)
 Cut off
 Sensitivity
 Specificity
Imbert-Bismut, 2001
 189
 Prospective
Single center
 ActiTest
 A2A3 / 0.33
 0.79 (0.03)
 0.10
0.30
0.60
0.80
 0.99
0.91
0.70
0.49
 0.07
0.42
0.75
0.88
Imbert-Bismut, 2001
 134
 Prospective
Single center
Validation cohort
 ActiTest
 A2A3 / 0.28
 0.75 (0.03)
 0.10
0.30
0.60
0.80
 1.00
0.94
0.67
0.42
 0.07
0.33
0.65
0.87
Poynard, 2003
 352
 Retrospective
Randomized trial
Multicenter
Before treatment
 ActiTest
 A2A3 / 0.83
 0.75 (0.03)
 0.10
0.30
0.60
0.80
 1.00
0.90
0.49
0.20
 0.00
0.38
0.87
0.99
Poynard, 2003
 352
 Retrospective
Randomized trial
Multicenter
After treatment
 ActiTest
 A2A3 / 0.39
 0.86 (0.02)
 0.10
0.30
0.60
0.80
 0.91
0.75
0.38
0.14
 0.59
0.83
0.98
0.996

Poynard et al. Comparative Hepatology 2004 3:8   doi:10.1186/1476-5926-3-8